Journal Article

Management of Rabies in Humans

Alan C. Jackson, Mary J. Warrell, Charles E. Rupprecht, Hildegund C. J. Ertl, Bernhard Dietzschold, Michael O'Reilly, Richard P. Leach, Zhen F. Fu, William H. Wunner, Thomas P. Bleck and Henry Wilde

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 1, pages 60-63
Published in print January 2003 | ISSN: 1058-4838
Published online January 2003 | e-ISSN: 1537-6591 | DOI:
Management of Rabies in Humans

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Rabies is a fatal disease in humans, and, to date, the only survivors of the disease have received rabies vaccine before the onset of illness. The approach to management of the rabies normally should be palliative. In unusual circumstances, a decision may be made to use an aggressive approach to therapy for patients who present at an early stage of clinical disease. No single therapeutic agent is likely to be effective, but a combination of specific therapies could be considered, including rabies vaccine, rabies immunoglobulin, monoclonal antibodies, ribavirin, interferon-α, and ketamine. Corticosteroids should not be used. As research advances, new agents may become available in the future for the treatment of human rabies.

Journal Article.  3073 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.